Literature DB >> 1138547

Pseudohypoparathyroidism. Disappearance of the resistance to parathyroid extract during treatment with vitamin D.

W Stögmann, J A Fischer.   

Abstract

Serum immunoreactive parathyroid hormone (iPTH) levels were increased in a 15 year old girl with pseudohypoparathyroidism, hypocalcemia, hyperphosphatemia, and minimal phosphaturic and absent hypercalcemic responses to exogenous parathyroid extract (PTE). Following normalization of the serum calcium concentration with vitamin D, serum iPTH and phosphate concentrations returned to the normal range, and phosphaturia could be clearly stimulated and hypercalcemia induced by PTE. On the other hand, the urinary cyclic adenosine 3',5'-monophosphate (cyclic AMP) excretion could not be stimulated, suggesting that in this case, there appears to be no relationship between the urinary excretion of cyclic AMP and the phosphaturic effect of PTE. The minimal phosphaturic effect and the lack of hypercalcemic effects of PTE in untreated pseudohypoparathyroidism can be explained by the secondary hyperparathyroidism causing elevated iPTH levels rather than by a defect at the level of the receptor sites. A requirement of pharmacologic amounts of vitamin D per se, however, for the responsiveness of patients with pseudohypoparathyroidism to PTE cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1138547     DOI: 10.1016/0002-9343(75)90332-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  Imprinting in Albright's hereditary osteodystrophy.

Authors:  S J Davies; H E Hughes
Journal:  J Med Genet       Date:  1993-02       Impact factor: 6.318

2.  Pseudohypoparathyroidism with normal phosphaturic response to exogenous parathyroid hormone administration.

Authors:  S O'Neill; F Walker; W F O'Dwyer
Journal:  Ir J Med Sci       Date:  1981-07       Impact factor: 1.568

3.  Resistance to the phosphaturic and calcemic actions of parathyroid hormone during phosphate depletion. Prevention by 1,25-dihydroxyvitamin D3.

Authors:  H J Gloor; J P Bonjour; J Caverzasio; H Fleisch
Journal:  J Clin Invest       Date:  1979-03       Impact factor: 14.808

4.  Regulation of circulating parathyroid hormone levels: normal physiology and consequences in disorders of mineral metabolism.

Authors:  J A Fischer; J W Blum; W Hunziker; U Binswanger
Journal:  Klin Wochenschr       Date:  1975-10-15

5.  Direct effect of calcitriol on the regulation of parathyroid hormone secretion in a case of pseudo-hypoparathyroidism (a 24-month follow-up study).

Authors:  P Giraud; M Audran; V Rohmer; P Jallet; M F Basle; C Bregeon; J C Bigorgne
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

6.  Familial pseudohypoparathyroidism without somatic anomalies.

Authors:  J S Winter; I A Hughes
Journal:  Can Med Assoc J       Date:  1980-07-05       Impact factor: 8.262

7.  Normocalcaemic pseudohypoparathyroidism with unusual phenotype.

Authors:  J M Gertner; S Tomlinson; J Gonzalez-Macias
Journal:  Arch Dis Child       Date:  1978-04       Impact factor: 3.791

8.  Secondary hyperparathyroidism with 1,25-dihydroxyvitamin D deficiency and pseudohypoparathyroidism in childhood: relationship between plasma 1,25-dihydroxyvitamin D and parathyroid hormone levels and urinary cyclic AMP response to exogenous PTH.

Authors:  Y Seino; M Ishida; K Yamaoka; T Shimotsuji; T Ishii; H Yabuuchi; M Fukase; T Fujita
Journal:  Eur J Pediatr       Date:  1981-02       Impact factor: 3.183

9.  Pseudohypoparathyroidism type I-b with neurological involvement is associated with a homozygous PTH1R mutation.

Authors:  R Guerreiro; J Brás; S Batista; P Pires; M H Ribeiro; M R Almeida; C Oliveira; J Hardy; I Santana
Journal:  Genes Brain Behav       Date:  2016-08-24       Impact factor: 3.449

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.